

Is Natamycin still in shortage in 2026? Get the latest update on Natacyn availability, pricing, and what patients can do to find it.
If you rely on Natamycin (brand name Natacyn) to treat a fungal eye infection, you've probably experienced the frustration of being told it's out of stock. For years, patients across the United States have dealt with difficulty finding this critical medication. But is Natamycin actually in shortage right now? And what does the landscape look like in 2026?
In this post, we'll give you the latest information on Natamycin availability, explain why it's been hard to find, cover the current cost picture, and share practical steps you can take to get the medication you need.
As of early 2026, Natamycin is not officially listed on the FDA Drug Shortage database. This means the FDA considers the market supply adequate based on manufacturer reports. However, "not in shortage" on the FDA's list doesn't always reflect the reality at your local pharmacy.
Natamycin has always been difficult to find at retail pharmacies — not because of a manufacturing shortage, but because of the drug's unique market position:
So even when supply is technically available from the manufacturer, individual patients can still struggle to find a pharmacy that has it on the shelf.
Natamycin's availability challenges aren't new. Here are the main factors that have contributed to difficulty finding this medication over the years:
Alcon Laboratories is the sole manufacturer of Natacyn in the United States. With no generic competition, any production hiccup — whether related to raw materials, quality control, or logistics — can temporarily reduce supply nationwide.
Natamycin is typically distributed through specialty pharmacy channels rather than standard retail wholesalers. This means your neighborhood CVS or Walgreens may not even be able to order it through their usual supply chain.
Over the years, there have been periodic reports of Natamycin supply disruptions. While these haven't always risen to the level of an official FDA shortage designation, they've been enough to leave patients and providers scrambling for alternatives.
Because Natamycin serves a small patient population, neither the manufacturer nor distributors maintain large inventory buffers. A small spike in demand — such as an outbreak of Fusarium keratitis — can quickly deplete available stock.
For a deeper dive into these supply dynamics, read our post on why Natamycin is so hard to find.
The cost of Natamycin remains high. Here's what you can expect to pay:
If cost is a barrier, our guide on how to save money on Natamycin covers discount cards, patient assistance programs, and other strategies to reduce your out-of-pocket expense.
While no new FDA-approved Natamycin products have entered the U.S. market as of early 2026, there are some developments worth noting:
For a full comparison of alternatives, see our post on alternatives to Natamycin.
If you need Natamycin today, here are the most effective steps you can take:
For a complete step-by-step guide, read our post on how to find Natamycin in stock near you.
While Natamycin is not officially in shortage as of 2026, the practical reality is that it remains one of the harder medications to find at a pharmacy. Its single-source status, niche market, specialty distribution, and high cost all contribute to ongoing availability challenges.
The good news is that the medication is being manufactured, and with the right tools and strategy, most patients can locate it within a day or two. Start with Medfinder, work with your ophthalmologist, and don't hesitate to explore compounded alternatives if you need treatment right away.
Fungal eye infections are serious and time-sensitive. Don't wait — take action today to secure the treatment you need.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.